Atomwise Inc. news
Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr as Chief Financial Officer and Jeffrey Cerio, Pharm.D., J.D. as General Counsel and Corporate Secretary. Lori Kunkel, M.D. and Ron Dror, Ph.D. have also joined the company’s Scientific Advisory Board.
Atomwise, a technology-enabled pharmaceutical company leveraging the power of artificial intelligence (AI) to revolutionize small molecule drug discovery, today announced that it has been invited to present next week at the 40th Annual J.P. Morgan Healthcare Conference.
Atomwise Chief Executive Officer and Co-Founder Abraham Heifets, Ph.D
Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline.
"This is the dream team," says Abraham Heifets, co-founder and CEO of Atomwise. "Mike Varney built Genentech`s small molecule capability, Bruce Roth discovered the
Atomwise, a leader in using artificial intelligence (AI) for small -molecule drug discovery, today announced it has been named to Fast Company`s prestigious annual list of the World`s Most Innovative Companies for 2021. Atomwise was recognized for its unmatched AI platform, AtomNet®?, as well as its growing pipeline and portfolio of partnerships and joint ventures tackling some of the most challenging targets in small molecule drug development.
Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech inno
The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule therapies in collaboration with the foundation’s global network
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today $2.3M in grant funding for AI-based discovery of an
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today a partnership with
CB Insights today named Atomwise to its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world.
The 2020 Digital Health 150 cohort highlight
Atomwise, the leader in using artificial intelligence (AI) for small molecule drug discovery, announced today it has fifteen research collaborations underway with leading global universities to explore broad-spectrum therapies for COVID-19 and other coronaviruses.
Coronaviruses are RNA viruses and include the causative SARS-CoV-2 strain of the current COVID-19 global pandemic as well as MERS and SARS-CoV-1 from prior regional outbr